UK Immunotherapy Study: Reanalysis by a combined symptom and medication score - 06/12/18
Doi : 10.1016/j.jaci.2018.07.034
Anthony J. Frew, MD a, Christian Ljørring, MSc b, Hendrik Wolf, PhD c, Eike Wüstenberg, MD c, d, Stephen R. Durham, MD e, Christopher J. Corrigan, PhD f, Richard J. Powell, MD g, Oliver Pfaar, MD h, i 
a Department of Respiratory Medicine, Royal Sussex County Hospital, Brighton, United Kingdom
b Global Clinical Development, ALK-Abelló, Hørsholm, Denmark
c ALK-Abelló Arzneimittel GmbH Clinical Development/Medical Department, Hamburg, Germany
d Universitätsklinikum Carl Gustav Carus, Clinic for Otolaryngology, Dresden, Germany
e Allergy and Clinical Immunology, Section Inflammation, Repair and Development, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, United Kingdom
f Department of Allergy, Guys Hospital, London and Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
g School of Molecular Medical Sciences, Faculty of Medicine and Health Science, University of Nottingham, Nottingham, United Kingdom
h Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
i Center for Rhinology and Allergology, Wiesbaden, Germany
| Supported by ALK-Abelló, Hørsholm, Denmark. |
|
| Disclosure of potential conflict of interest: C. Ljørring, H. Wolf, and E. Wüstenberg report personal fees from employment and personal fees from stock/stock options from ALK-Abelló outside the submitted work. S. R. Durham reports grants from ALK-Abelló during the conduct of the study; personal fees from ALK-Abelló, Adiga, Allergy Therapeutics, ASIT Biotech, and Biomay; grants from GlaxoSmithKline; and personal fees from UCB outside the submitted work. C. J. Corrigan reports grants from ALK-Abelló during the conduct of the study and other support from GlaxoSmithKline outside the submitted work. O. Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, and Lofarma; grants from Biomay, Nuvo, and Circassia; grants and personal fees from Biotech Tools S.A. and Laboratorios LETI/LETI Pharma; personal fees from Novartis Pharma and MEDA Pharma; grants and personal fees from Anergis S.A.; personal fees from Mobile Chamber Experts (a GA2LEN partner), Pohl-Boskamp, and Indoor Biotechnologies; and grants from GlaxoSmithKline outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 6
P. 1998 - décembre 2018 Retour au numéro
Article précédent
- A novel allergen-specific therapy with CD40-silenced B cells and dendritic cells
- Motohiko Suzuki, Makoto Yokota, Yoshihisa Nakamura, Shinya Ozaki, Shingo Murakami
- Risk factors for Haemophilus influenzae and pneumococcal respiratory tract colonization in CVID
- Federica Pulvirenti, Romina Camilli, Maria Giufrè, Cinzia Milito, Fernanda Pimentel de Araujo, Fabiola Mancini, Rita Cardines, Alessandra Ciervo, Annalisa Pantosti, Marina Cerquetti, Isabella Quinti
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?